The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...